Literature DB >> 9382911

Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study.

U Heininger1, K Klich, K Stehr, J D Cherry.   

Abstract

OBJECTIVE: To study the clinical presentation of culture-confirmed pertussis in children and their contacts with cough illnesses in an outpatient setting.
METHODOLOGY: In conjunction with a large pertussis vaccine efficacy trial in Germany, a central laboratory to isolate Bordetella species from nasopharyngeal specimens was established in Erlangen in October 1990. Pediatricians in private practices in southern Germany, the Saar region, and Berlin were encouraged to obtain nasopharyngeal specimens and clinical characteristics from patients with cough illnesses >/=7 days' duration. Bordetella species were isolated by use of calcium alginate swabs, Regan-Lowe agar, and modified Stainer-Scholte broth. Clinical characteristics were determined by initial and follow-up questionnaires.
RESULTS: From October 1990 to September 1996, 20 972 specimens were submitted, and B pertussis was isolated in 2592 instances (12.4%). Of the culture-proven cases, 50.7% were female, and the age range was 6 days to 41 years, with a mean and median of 4.3 years and 4.1 years, respectively. The following characteristics were noted. Only 4% of the patients had received pertussis vaccine. Of unvaccinated patients, 90.2% had paroxysmal cough, 78.9% demonstrated whooping, and 53.3% presented with posttussive vomiting; 5.7% had fever >/=38 degrees C. The duration of cough was </=4 weeks in 37.9% and </=3 weeks in 17.4%. Leukocytosis and lymphocytosis (values above the age-specific mean) were observed in 71.9% and 75.9% of unvaccinated patients, respectively. The overall complication rate was 5.8%, and pneumonia (29%) was the most frequent complication. In infants <6 months of age, the rate of complications was 23.8%. One death in a 7-month-old infant occurred.
CONCLUSIONS: Typical symptoms of pertussis were observed in the great majority of patients regardless of age group. However, the duration of cough was surprisingly short in one sixth of the patients. These short illness cases would not be classified as pertussis according to the World Health Organization clinical case definition, which requires >/=21 days of spasmodic cough.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9382911     DOI: 10.1542/peds.100.6.e10

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  26 in total

1.  Peptidoglycan Recognition Protein 4 Suppresses Early Inflammatory Responses to Bordetella pertussis and Contributes to Sphingosine-1-Phosphate Receptor Agonist-Mediated Disease Attenuation.

Authors:  Ciaran Skerry; William E Goldman; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.

Authors:  Andrew L Baughman; Kristine M Bisgard; Kathryn M Edwards; Dalya Guris; Michael D Decker; Kathy Holland; Bruce D Meade; Freyja Lynn
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

Review 3.  Diagnosis and management of pertussis.

Authors:  Alberto E Tozzi; Lucia Pastore Celentano; Marta Luisa Ciofi degli Atti; Stefania Salmaso
Journal:  CMAJ       Date:  2005-02-15       Impact factor: 8.262

4.  Evaluation of two vaccine education interventions to improve pertussis vaccination among pregnant African American women: A randomized controlled trial.

Authors:  Jennifer L Kriss; Paula M Frew; Marielysse Cortes; Fauzia A Malik; Allison T Chamberlain; Katherine Seib; Lisa Flowers; Kevin A Ault; Penelope P Howards; Walter A Orenstein; Saad B Omer
Journal:  Vaccine       Date:  2017-02-16       Impact factor: 3.641

Review 5.  Pertussis leukocytosis: mechanisms, clinical relevance and treatment.

Authors:  Nicholas H Carbonetti
Journal:  Pathog Dis       Date:  2016-09-07       Impact factor: 3.166

6.  Fatal Pertussis in the Neonatal Mouse Model Is Associated with Pertussis Toxin-Mediated Pathology beyond the Airways.

Authors:  Karen M Scanlon; Yael G Snyder; Ciaran Skerry; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2017-10-18       Impact factor: 3.441

Review 7.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

8.  Reduction of Pertussis Inflammatory Pathology by Therapeutic Treatment With Sphingosine-1-Phosphate Receptor Ligands by a Pertussis Toxin-Insensitive Mechanism.

Authors:  Ciaran Skerry; Karen Scanlon; Jeremy Ardanuy; Drew Roberts; Li Zhang; Hugh Rosen; Nicholas H Carbonetti
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

9.  Quantification of the adenylate cyclase toxin of Bordetella pertussis in vitro and during respiratory infection.

Authors:  Joshua C Eby; Mary C Gray; Jason M Warfel; Christopher D Paddock; Tara F Jones; Shandra R Day; James Bowden; Melinda D Poulter; Gina M Donato; Tod J Merkel; Erik L Hewlett
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

10.  Pertussis in early life: underdiagnosed, severe, and risky disease. A seven-year experience in a pediatric tertiary-care hospital.

Authors:  Chiara Di Camillo; Anna Chiara Vittucci; Livia Antilici; Claudia Ciarlitto; Giulia Linardos; Carlo Concato; Laura Lancella; Alberto Villani
Journal:  Hum Vaccin Immunother       Date:  2020-08-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.